|
業務類別
|
Biotechnology |
|
業務概覽
|
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371. |
| 公司地址
| 80 Guest Street, Suite 601, Boston, MA, USA, 02135 |
| 電話號碼
| +1 617 500-8099 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.compasstherapeutics.com |
| 員工數量
| 39 |
| Mr. Jonathan Anderman, J.D. |
General Counsel and Corporate Secretary |
美元 450.00K |
29/04/2026 |
| Dr. Thomas J. Schuetz, M.D.,PhD |
Chief Executive Officer and Vice Chairman of the Board |
美元 630.00K |
29/04/2026 |
| Mr. Arjun Prasad, M.B.A.,M.P.H. |
Chief Commercial Officer |
-- |
29/04/2026 |
| Dr. Cynthia Sirard, M.D. |
Chief Medical Officer |
-- |
29/04/2026 |
| Mr. Barry Shin, J.D.,M.B.A. |
Chief Financial Officer |
美元 480.00K |
29/04/2026 |
| Mr. Neil Lerner, C.P.A. |
Senior Vice President and Chief Accounting Officer |
-- |
29/04/2026 |
| Dr. Bing Gong, PhD |
Chief Scientific Officer |
-- |
29/04/2026 |
|
|
| Dr. Carl L. Gordon, C.F.A.,PhD |
Chairman of the Board |
29/04/2026 |
| Ms. Ellen V. Chiniara, J.D. |
Independent Director |
29/04/2026 |
| Dr. Thomas J. Schuetz, M.D.,PhD |
Chief Executive Officer and Vice Chairman of the Board |
29/04/2026 |
| Dr. Mary Ann Gray,PhD |
Independent Director |
29/04/2026 |
| Dr. Philip J. Ferneau, J.D.,M.B.A. |
Independent Director |
29/04/2026 |
| Mr. James P. Boylan, M.B.A. |
Independent Director |
29/04/2026 |
| Mr. Richard S. Lindahl |
Independent Director |
29/04/2026 |
|
|
|
|
